David Lieberman MD
Professor Emeritus, Department of Medicine; Former Chief, Division of Gastroenterology and Hepatology, Oregon Health and Science University (OHSU), Portland, OregonDavid Lieberman, MD, is Professor of Medicine and was Chief of the Division of Gastroenterology and Hepatology at Oregon Health and Science University (1997-2021) in Portland, Oregon, and the Portland VA Medical Center. Dr. Lieberman is internationally recognized as an expert on colon cancer screening. He is Chairman for VA Cooperative Study # 380, which utilized colonoscopy to screen asymptomatic subjects for colorectal cancer with publications in New England Journal of Medicine, JAMA, Annals of Internal Medicine and Gastroenterology. Dr. Lieberman was the Chairman of the Multi-Society Task Force on Colorectal Cancer (2006-2012), and authored colon cancer screening recommendations in 2008 (CA and Gastroenterology) as well as colonoscopy quality indicators in 2007, review of colorectal cancer screening (JAMA 2016), and recommendations for polyp surveillance (2012 and 2020).
He was the Director of the Clinical Outcomes Research Initiative (CORI), supported by NIH 1999-2016. The project created a national endoscopic data repository for research, with more than 90 peer-reviewed publications to date. Dr. Lieberman served as a member of the National Commission on Digestive Diseases from 2006-2008, President of the American Society for Gastrointestinal Endoscopy (ASGE) in 2001-2002, and Associate Editor of Gastroenterology (2011-2013). He was President of the AGA Institute (2018-2019) and AGA (2019-2020), and Chair of the AGA Colorectal Cancer Task Force (2021-present). He has been an advisor to the President’s Cancer Panel (2020-2021).
Recent Contributions to PracticeUpdate:
- Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance
- Effect of Fecal Immunochemical Test Screening on the Risk of Colorectal Cancer Mortality
- Obesity and Polygenic Risk Score as Risk Factors for Colorectal Neoplasms
- Prevalence of Sessile Serrated Lesions in Individuals With Positive FIT Results Undergoing Colonoscopy
- Blood-Based Colorectal Cancer Screening in an Integrated Health System
- Association of Serrated Polyp Detection Rates With Post-Colonoscopy Colorectal Cancer
- Risk-Adapted Starting Age for Personalized Colorectal Cancer Screening
- Fecal Microbial DNA Markers Serve for Screening Colorectal Neoplasm in Asymptomatic Individuals
- Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection
- Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors